Press release
Global Pneumococcal Vaccines Market Set for Robust Growth, Projected to Exceed USD 13.3 Billion by 2033 advance at a CAGR of 4.1% | FMI
Pneumococcal Vaccines Market
Pneumococcal vaccines play a vital role in preventing infections caused by Streptococcus pneumoniae bacteria, a major contributor to respiratory and bloodstream infections globally. These vaccines are critical in reducing morbidity and mortality rates, making them an essential tool in the global healthcare system's efforts to combat preventable diseases.
๐๐๐ญ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐ข๐ง๐ญ๐จ ๐๐๐ซ๐ค๐๐ญ ๐๐จ๐ฏ๐๐ฆ๐๐ง๐ญ๐ฌ: ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ! https://www.futuremarketinsights.com/report-sample#5245502d47422d37303738
Several factors are contributing to this steady market growth, including a heightened global awareness of preventive healthcare and continuous advancements in vaccine technology. The increasing emphasis on widespread vaccination coverage is creating fertile ground for industry leaders to innovate and forge strategic partnerships.
Future Market Insights highlights the critical role of innovation and collaboration among key industry players in maintaining the upward trajectory of the pneumococcal vaccines market. The report serves as an essential resource for stakeholders looking to navigate the evolving landscape of pneumococcal vaccines and capitalize on growth opportunities in the years ahead.
As the global healthcare community intensifies efforts to fight preventable diseases, pneumococcal vaccines remain a cornerstone in the battle against infections worldwide.
๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ ๐๐ง๐๐ฎ๐ฆ๐จ๐๐จ๐๐๐๐ฅ ๐๐๐๐๐ข๐ง๐๐ฌ ๐๐๐ซ๐ค๐๐ญ:
โข The pneumococcal vaccines market has witnessed an unprecedented surge of USD 0.4 Billion from the base year to the current.
โข The pneumococcal vaccines market is estimated to advance forward at a moderate pace, registering a CAGR of 4.1% through the forecast period.
โข The Prevenar-13 segment by product type category has accounted for the highest share of the pneumococcal market with USD 9,500 Million in 2023.
โข The public authorities segment by distribution channel category is estimated to hold dominant shares, trailing at a CAGR of 6.8% through the projection period.
"The growing demand for effective vaccination programs to prevent pneumococcal infections underscores the market's immense potential for growth," said a representative from Future Market Insights. "As healthcare infrastructures continue to evolve, the focus on comprehensive immunization strategies is expected to drive the expansion of the pneumococcal vaccines market."
๐๐ง๐๐ซ๐๐๐ฌ๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฆ๐๐ง๐: ๐๐๐ญ ๐๐ง-๐๐๐ฉ๐ญ๐ก ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐ง๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐๐ฎ๐ซ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐๐๐ฉ๐จ๐ซ๐ญ! https://www.futuremarketinsights.com/reports/pneumococcal-vaccines-market
๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐๐ง๐๐ฌ๐๐๐ฉ๐:
Leading Industry Players Illuminate Opportunities Amidst Technological Advancements The pneumococcal vaccines market thrives in its diversity, as major manufacturers employ a variety of strategies to stay ahead of the competition. Through both organic growth and strategic acquisitions, industry giants are investing heavily in research and development to enhance the efficacy of pneumococcal vaccines, particularly in addressing chronic illnesses prevalent among aging populations.
Activirosomes, for instance, pioneers the development of viral infection vaccines. Harnessing active virosome technology, the company engineers non-replicating derivatives of measles and other viruses, focusing solely on essential viral genes that trigger robust immune responses.
๐๐๐๐๐ง๐ญ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ๐ฌ:
โข In September 2020, a Japanese pharmaceutical company, Shinogi, made an announcement to enter into a license agreement with Hanavax, a next-generation nasal vaccine manufacturer. The agreement was likely to assist the company in research and development activities, commercialization, manufacturing, and distribution of Streptococcus pneumonia vaccines developed by Hanavax.
โข In December 2019, China-based biotechnology company, Walvax Biotechnology Co., Ltd. received approval from the regulatory body of China, the National Medical Products Administration for its pneumococcal-13 valent conjugate vaccine. This vaccine is also estimated to act as an alternative to Prevnar-13 for immunizing children in the age group of 6 months to 5 years.
โข In January 2018, Pfizer, one of the global leaders in the pharmaceutical industry made an announcement to reduce the price of the PCV-13 4-dose vial vaccine from USD 3.05 to USD 2.95 per dosage in the Gavi-supported countries.
๐๐จ๐ฆ๐ ๐จ๐ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐ฉ๐ซ๐จ๐ฅ๐ข๐๐๐ซ๐๐ญ๐ข๐ง๐ ๐ข๐ง ๐ญ๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐ซ๐:
โข Astellas Pharma Inc
โข GlaxoSmithKline Plc
โข Merck & Co. Inc
โข Panacea Biotech Ltd
โข Pfizer Inc
โข Sanofi S.A
โข Walvax Biotechnology Co. Ltd
โข CSL Ltd
โข Serum Institute of India Pvt. Ltd
โข Talley Group Ltd
๐ ๐ฎ๐ญ๐ฎ๐ซ๐-๐๐ซ๐จ๐จ๐ ๐๐จ๐ฎ๐ซ ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐๐ฎ๐ซ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ! https://www.futuremarketinsights.com/industry-analysis/therapy-area
๐๐๐ฒ ๐๐๐ ๐ฆ๐๐ง๐ญ๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐ง๐๐ฎ๐ฆ๐จ๐๐จ๐๐๐๐ฅ ๐๐๐๐๐ข๐ง๐๐ฌ ๐๐๐ซ๐ค๐๐ญ:
๐๐ฒ ๐๐ซ๐จ๐๐ฎ๐๐ญ ๐๐ฒ๐ฉ๐:
โข Pneumococcal Polysaccharide Vaccines
โข Pneumococcal Conjugate Vaccines
๐๐ฒ ๐๐ข๐ฌ๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ข๐จ๐ง ๐๐ก๐๐ง๐ง๐๐ฅ:
โข Pharmacies
โข Community Clinics
โข Public Health Agencies
โข Others
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง:
โข North America
โข Latin America
โข Asia Pacific
โข Middle East and Africa (MEA)
โข Europe
๐๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ ๐ ๐๐'๐ฌ ๐๐๐ฅ๐๐ญ๐๐ ๐๐ง๐ ๐จ๐ข๐ง๐ ๐๐จ๐ฏ๐๐ซ๐๐ ๐ ๐จ๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐๐จ๐ฆ๐๐ข๐ง:
๐๐ง๐๐ฎ๐ฆ๐จ๐ง๐ข๐ ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐๐จ๐ซ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐: https://www.futuremarketinsights.com/reports/pneumonia-diagnostic-market
๐๐ฑ๐ข๐ฅ๐ฅ๐๐ซ๐ฒ ๐๐ฒ๐ฉ๐๐ซ๐ก๐ข๐๐ซ๐จ๐ฌ๐ข๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐: https://www.futuremarketinsights.com/reports/axillary-hyperhidrosis-treatment-market
๐๐๐๐ญ๐๐ฆ๐ข๐ง๐จ๐ฉ๐ก๐๐ง ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐: https://www.futuremarketinsights.com/reports/acetaminophen-market
๐๐๐๐ฌ๐จ๐ง๐๐ฅ ๐๐๐๐๐๐ญ๐ข๐ฏ๐ ๐๐ข๐ฌ๐จ๐ซ๐๐๐ซ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐๐ฆ๐๐ง๐ ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐: https://www.futuremarketinsights.com/reports/seasonal-affective-disorder-therapeutics-market
๐๐ง๐๐ฆ๐ข๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐: https://www.futuremarketinsights.com/reports/aemia-treatment-market
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Pneumococcal Vaccines Market Set for Robust Growth, Projected to Exceed USD 13.3 Billion by 2033 advance at a CAGR of 4.1% | FMI here
News-ID: 3850687 • Views: โฆ
More Releases from Future Market Insights Inc
Endoscopy Fluid Management Systems Market Poised for Significant Growth, Project โฆ
The global Endoscopy Fluid Management Systems Market is on a trajectory of significant expansion, with a new market forecast projecting its value to more than double over the next decade. According to the latest analysis, the market, valued at an estimated USD 550.3 million in 2025, is expected to surge to USD 1,123.7 million by 2035. This robust growth represents a compound annual growth rate (CAGR) of 7.4% and isโฆ
NGS Sample Preparation Market Poised for Explosive Growth, Set to Triple by 2035 โฆ
A new market analysis projects the global Next-Generation Sequencing (NGS) Sample Preparation market to experience a significant surge, forecasting a valuation of USD 7.0 billion by 2035. This marks a substantial increase from its estimated USD 1.9 billion value in 2025, reflecting a robust Compound Annual Growth Rate (CAGR) of 13.7% over the decade. The findings underscore the pivotal role of sample preparation in the expanding field of genomics, drivenโฆ
Eye and Face Protection Market USD 2.3 Billion by 2035 Key Players Medline Indus โฆ
The global Eye and Face Protection Market is poised for significant expansion, with a new forecast predicting it will grow from an estimated USD 859.3 million in 2025 to USD 2,332.2 million by 2035. This robust growth trajectory represents a compound annual growth rate (CAGR) of 10.5% over the forecast period, driven by a confluence of rising industrial safety awareness, stringent regulatory mandates, and technological innovation.
Click Here for More Information:-โฆ
Dermatology Excimer Lasers Market to Nearly Triple by 2035 Key Players Cutera, I โฆ
The global market for dermatology excimer lasers is projected to surge from an estimated USD 109.7 million in 2025 to a remarkable USD 317.1 million by 2035, marking a significant compound annual growth rate (CAGR) of 11.2%. This substantial expansion is being fueled by a combination of factors, including the rising global prevalence of chronic skin conditions and a growing preference for advanced, targeted therapies.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/dermatology-excimer-lasers-market
Dermatologyโฆ
More Releases for Pneumococcal
Key Influencer in the Pneumococcal Vaccine Market 2025: Rising Prevalence Of Pne โฆ
What combination of drivers is leading to accelerated growth in the pneumococcal vaccine market?
The escalating occurrence of pneumococcal infections is projected to boost the pneumococcal vaccine market's growth. Pneumococcal infections represent any condition triggered by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This includes illnesses like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies against these bacteria, thereby minimizing orโฆ
Pneumococcal Vaccine Market to see Huge Growth by 2029
The global pneumococcal vaccine market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market includes the increasing efforts to curb pneumonia among children in developed countries. Whereas, in the developing countries, the increasing spending on infrastructure and rising awareness towards vaccines, are the factors, which are expected to fuel the market growth during the forecasted period.
According to theโฆ
Pneumococcal Vaccines Market - Preventing Pneumonia: Safeguarding Health with Pn โฆ
Newark, New Castle, USA: The "Pneumococcal Vaccines Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pneumococcal Vaccines Market: https://www.growthplusreports.com/report/pneumococcal-vaccines-market/7761
This latest report researches the industry structure, sales, revenue,โฆ
Global To Invigorate The Intravenous Pneumococcal Vaccines Market
Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than two years of age, all adults 65 years or older, and for people 2-64 years old with certain medical conditions. The CDC recommends pneumococcal polysaccharide vaccine for allโฆ
Pneumococcal Vaccines Market Demands and Gross Margin 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industryโฆ
Pneumococcal Vaccine Report on Global Pneumococcal Vaccine Market Development, p โฆ
Latest Survey on Pneumococcal Vaccine Market:
The Global Pneumococcal Vaccine market report value has been estimated considering the application and regional segments, market share, and size, while the forecast for each product type and application segment has been provided for the global markets. The Pneumococcal Vaccine report offers detailed profiles of the key players to bring out a clear view of the competitive landscape of the Pneumococcal Vaccine Outlook. It alsoโฆ
